⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Official Title: Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial

Study ID: NCT02404506

Interventions

Eribulin mesilate

Study Description

Brief Summary: Breast cancer is the most frequent malignancy in women, world-wide the leading cause of cancer mortality. One of the strongest risk factors for developing breast cancer is age, with a prevalence approaching 7% in women \>70 years; more than 40% of breast cancer patients are older than 65 years. Although the survival rate has increased in the last years, about one third of patients will relapse with distant metastases. Treatment for patients with metastatic breast cancer is palliative, therefore maintaining or improving quality of life. The use of taxanes and anthracyclines as first line chemotherapy regimen for metastatic breast cancer is widely accepted. Both taxanes and anthracyclines have considerable side effects, especially in elderly patients. Eribulin, a synthetic analogue of a chemotherapeutically active compound derived from the sea sponge Halichondria okadai, acts as an inhibitor of microtubule dynamics. It is registered as palliative chemotherapy in advanced breast cancer after anthracyclines and taxanes. Studies with eribulin treatment have shown similar efficacy compared to anthracyclines and taxanes, but less toxicity. Those studies showed that often the dose of eribulin had to be reduced during treatment due to toxicity without compromising the efficacy of the treatment. The main objective of the trial is to explore the efficacy of a reduced starting dose of eribulin as first-line treatment in elderly metastatic breast cancer patients. The secondary objective of the trial is to investigate the safety of eribulin in those patients. Eribulin mesilate 1.1mg/m2 i.v. will be administered intravenously every 3 weeks on day 1 and day 8 until progressive disease.

Detailed Description: Due to a rising number of elderly patients, fit for chemotherapy, investigating a well-tolerated and effective first line treatment is warranted. In this specific population often there are contra-indications for the use of standard first line drugs like anthracyclines and taxanes due to comorbidities (e.g. cardiac impairment or Peripheral neuropathy). Response rates in first line treatment with taxanes and anthracyclines usually do not exceed 30%. Eribulin has shown a response rate of 29% and a clinical benefit rate (corresponding to the investigators primary endpoint) of 52% in first line, so the investigators expect similar efficacy, but less toxicity. Optimal dose, schedule and tolerability of this drug in the first line setting are unknown in the elderly population. No information on dose modifications in this population is available. Based on the data of eribulin in the first line with higher efficacy in those patients with dose reductions, the SAKK 25/14 trial investigates the reduced starting-dose of eribulin of 1.1mg/m2 for this vulnerable population of elderly patients. Growth factors to maintain a certain dose level of eribulin are not recommended, respecting the international guidelines. SAKK has a tradition in conducting trials in the elderly population, such as SAKK 25/99 in metastatic breast cancer, SAKK 38/08 in aggressive B-cell-Lymphoma, SAKK 41/10 in metastatic colorectal cancer.

Eligibility

Minimum Age: 70 Years

Eligible Ages: OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Kantonsspital Aarau, Aarau, , Switzerland

Kantonsspital Baden, Baden, , Switzerland

Universitaetsspital-Basel, Basel, , Switzerland

Praxis für ambulante Tumortherapie, Basel, , Switzerland

Istituto Oncologico della Svizzera Italiana, Bellinzona, , Switzerland

Klinik Engeried / Oncocare, Bern, , Switzerland

Inselspital, Bern, Bern, , Switzerland

Spitalzentrum Biel, Biel, , Switzerland

Kantonsspital Graubünden, Chur, , Switzerland

Kantonsspital Frauenfeld / Brustzentrum Thurgau, Frauenfeld, , Switzerland

HFR Fribourg - Hôpital cantonal, Fribourg, , Switzerland

Clinique de Genolier, Genolier, , Switzerland

Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland

Clinica Sant'Anna - Oncologia Varini & Calderoni & Christinat, Lugano, , Switzerland

Kantonsspital Luzern, Luzerne, , Switzerland

Onkologie Zentrum Spital Männedorf, Männedorf, , Switzerland

Kantonsspital Olten, Olten, , Switzerland

Rundum Onkologie am Bahnhofpark, Sargans, , Switzerland

Onkologiezentrum Bürgerspital Solothurn, Solothurn, , Switzerland

Onkologiepraxis Dr. med. Isabella Schönenberger, St. Gallen, , Switzerland

Tumorzentrum ZeTUP, St. Gallen, , Switzerland

Kantonsspital - St. Gallen, St. Gallen, , Switzerland

Regionalspital, Thun, , Switzerland

Kantonsspital Winterthur, Winterthur, , Switzerland

Onkozentrum - Klinik im Park, Zurich, , Switzerland

Brust-Zentrum AG Zürich, Zürich, , Switzerland

Contact Details

Name: Ursula Hasler-Strub, MD

Affiliation: Cantonal Hospital of St. Gallen

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: